Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a radiopharmaceutical-focused company whose news flow centers on diagnostic imaging products, radiopharmaceutical pipeline progress and corporate developments. The company describes its purpose as enabling clinicians to "Find, Fight and Follow" disease, and its announcements frequently highlight advances in PET radiodiagnostics, oncology imaging agents and Alzheimer’s disease diagnostics.
News about Lantheus often covers regulatory milestones for its radiopharmaceutical pipeline. Recent releases include U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application for a new formulation of its piflufolastat F 18 PSMA PET imaging agent, a PDUFA date for LNTH-2501 (Ga 68 edotreotide) for somatostatin receptor-positive neuroendocrine tumors, and FDA acceptance of an NDA for MK-6240, a tau-targeted PET imaging agent for Alzheimer’s disease. These updates provide insight into how the company is expanding its diagnostic portfolio in oncology and neurology.
Lantheus news also frequently addresses business development and portfolio shaping. The company has reported acquisitions of Evergreen Theragnostics and Life Molecular Imaging, adding assets such as OCTEVY and Neuraceq and expanding its capabilities across the radiopharmaceutical value chain. It has also announced the divestiture of its SPECT business to SHINE Technologies, along with licensing agreements such as an exclusive deal with GE HealthCare to develop, manufacture and commercialize PYLARIFY in Japan.
Investors and healthcare professionals following LNTH news can also expect quarterly earnings releases, stock repurchase program announcements, leadership transition updates and conference participation notices. Together, these items provide context on Lantheus’ financial performance, capital allocation, governance and strategic direction in the radiopharmaceutical and medical imaging space.
Lantheus Holdings (NASDAQ: LNTH) has scheduled its third quarter 2024 earnings conference call and webcast for November 6, 2024, at 8:00 a.m. ET. The company will discuss its financial and operating results during this call. Participants are encouraged to register 15 minutes before the scheduled start time at the investor relations website to avoid delays. A replay will be available approximately two hours after the webcast ends and will remain accessible for at least 30 days.
Lantheus Holdings (NASDAQ: LNTH) presented results from the Phase 3 SPLASH trial of 177Lu-PNT2002, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study met its primary endpoint, showing significant improvement in radiographic progression-free survival (rPFS) with a median of 9.5 months for 177Lu-PNT2002 vs 6.0 months for ARPI control (HR 0.71, p=0.0088). Overall Response Rate was 38.1% vs 12.0%, including 9.3% Complete Responses. Patients showed statistically significant improvement in time to reduction of health-related quality of life. Interim Overall Survival data continue to mature, with crossover-adjusted Hazard Ratios <1.00 using various methods. 177Lu-PNT2002 demonstrated a favorable safety profile compared to ARPI control.
Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, has appointed Julie Eastland to its Board of Directors, effective September 3, 2024. Ms. Eastland, an experienced biotechnology and financial executive, will serve as an independent director and member of the Board's Audit Committee. With her addition, the Board now comprises ten directors, eight of whom are independent.
Ms. Eastland brings extensive expertise in finance, strategic planning, operations, and transactions within the biotechnology sector. She currently serves on the boards of Dynavax Technologies and Veana Therapeutics. Her previous roles include CEO of Harpoon Therapeutics and executive positions at ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics.
Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Brian Markison will present on Wednesday, September 4, at 7:45 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investors section of Lantheus' website at www.lantheus.com. The company will make a replay of the webcast available on its website for at least 30 days following the live presentation.
This conference participation underscores Lantheus' commitment to engaging with the investment community and sharing insights into its business focused on enabling clinicians to Find, Fight and Follow disease for improved patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced that additional clinical data from the Phase 3 Pivotal SPLASH Trial for PNT2002 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) will be presented at the ESMO Congress 2024. The presentation, titled 'Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)', will be delivered by Dr. Oliver Sartor from the Mayo Clinic on September 15, 2024. This presentation will include new data from the initial December 2023 readout, potentially providing important insights into the efficacy of PNT2002 for treating advanced prostate cancer.
Lantheus Holdings (NASDAQ: LNTH) reported strong Q2 2024 financial results with worldwide revenue of $394.1 million, up 22.5% year-over-year. Key highlights include:
- PYLARIFY sales reached $273.3 million, up 29.8%
- DEFINITY sales grew 10.7% to $78.1 million
- Adjusted EPS increased 16.4% to $1.80
- Cash and equivalents grew to $757.0 million
The company completed three strategic transactions to expand its innovative pipeline, including acquisitions in Alzheimer's disease and oncology. Lantheus maintains its full-year 2024 revenue guidance but updated EPS guidance due to these strategic investments.
Lantheus Holdings (NASDAQ: LNTH) has announced its upcoming second quarter 2024 earnings conference call and webcast, scheduled for July 31, 2024, at 8:00 a.m. Eastern Time. The event will provide an opportunity for stakeholders to learn about the company's financial and operating results for Q2 2024. Participants are encouraged to register online at the investor relations website, preferably fifteen minutes before the start time to avoid delays. A replay of the webcast will be available approximately two hours after completion and will remain archived on the same web page for at least 30 days.
Lantheus Holdings (NASDAQ: LNTH) has acquired Meilleur Technologies, Inc., gaining worldwide exclusive rights to NAV-4694, a Phase 3 ß amyloid PET imaging agent for Alzheimer's disease. This acquisition expands Lantheus' Alzheimer's diagnostic portfolio, complementing their existing tau-targeting agent MK-6240. The move aligns with updated NIA-AA guidelines recommending biomarkers for Alzheimer's diagnosis.
The deal involves an upfront payment, potential milestone payments, and royalties. Lantheus aims to advance NAV-4694 through pivotal trials and commercialization. With nearly 12 million Americans living with mild cognitive impairment or Alzheimer's, and projections of over 20 million by 2050, this acquisition strengthens Lantheus' position in the growing neurology market.
Lantheus Holdings announced its support for the Centers for Medicare & Medicaid Services' (CMS) proposed 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule, which aims to enhance payment for specialized diagnostic radiopharmaceuticals. CMS proposes separate payments for diagnostic radiopharmaceuticals costing over $630 per day, including Lantheus' PYLARIFY, instead of bundling these costs into nuclear medicine tests. The proposed rule includes a 60-day comment period ending September 9, 2024, with the final rule to be issued in early November and effective January 1, 2025. CEO Brian Markison highlighted the importance of equitable access to diagnostic radiopharmaceuticals for better patient outcomes.
Lantheus has appointed Jamie Spaeth as Chief People Officer, effective July 8, 2024. Ms. Spaeth joins the executive team, bringing nearly 20 years of HR experience in the biotech and pharma industries. Most recently, she served as Chief People Officer at Corium, a biopharmaceutical company.
Her responsibilities will include fostering a collaborative culture and supporting talent development to enhance Lantheus' strategy as a leading radiopharmaceutical-focused company. Ms. Spaeth's background includes roles at Sage Therapeutics and Shire, and she holds degrees in Hospitality and Tourism Management and Human Resources.
The addition of Ms. Spaeth is expected to strengthen Lantheus' leadership and support its mission of delivering better patient outcomes.